The Road To Restoring Credibility: How Maintaining A Good Reputation With FDA Can Be An Uphill Battle For Manufacturers – But It's Possible
This article was originally published in The Gray Sheet
Executive Summary
From our digital archives: Manufacturers can develop a bad reputation with FDA for a variety of reasons, including failing to systemically fix problems or follow through on commitments. “It’s tiresome, frankly, as a regulator, to have firms come in and pay lip service to the steps that they’re going to take, and then not follow up to demonstrate that they’ve taken those steps,” former CDRH Office of Compliance Director Steven Silverman said in December 2011. Two former agency officials also pointed out why FDA doesn’t trust some companies. Plus: A former Gambro Renal Products official explained how that firm's staff worked to change FDA’s perception of the company after it imposed an import ban on the firm in 2006.
You may also be interested in...
Speaking Of Medtech, Ep. 10: FDA’s TAP Pilot
In this FINAL EPISODE of Speaking Of Medtech: The US FDA got something it desperately wanted in its latest user-fee package with industry: a Total Product Lifecycle Advisory Program pilot, or TAP. The agency says TAP will allow for earlier and more frequent engagement with developers – but is it needed?
Thumbs Up: FDA Authorizes Weight Loss Suturing Systems From Apollo Endosurgery
People with obesity now have new tools to help them lose weight, thanks to the US agency’s de novo authorization.
FDA Slaps High Risk Class I Label On Recall Of COVID-19 Diagnostics Made In Uncontrolled Plant
More than 160,000 of the tests were recalled, including 104,900 COVID Test Kits Nonsterile and 61,500 Clean Catch Urine Kits.